X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Alogliptin Benzoate,Pioglitazone
Therapeutic Area: Endocrinology Product Name: Liovel
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Teijin Pharma
Deal Size: $1,250.0 million Upfront Cash: Undisclosed
Deal Type: Divestment April 01, 2021
Details:
The portfolio divested to Teijin Pharma was comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Alogliptin Benzoate
Therapeutic Area: Endocrinology Product Name: Nesina
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Teijin Pharma
Deal Size: $1,250.0 million Upfront Cash: Undisclosed
Deal Type: Divestment February 26, 2021
Details:
The portfolio to be divested to Teijin Pharma is comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tolvaptan
Therapeutic Area: Endocrinology Product Name: Samsca
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
Details:
Oral vasopressin V2-receptor antagonists Samsca® Tablets, Samsca® OD Tablets and SAMSCA® Granules 1% have received regulatory approval in Japan for the indication of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in adults.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
